Introduction
Breast cancer is the most commonly diagnosed cancer in women after non-melanoma skin cancer, and is the second leading cause of cancer deaths among women in the US (Jemal et al. 2010) . The contribution of genetic susceptibility to breast cancer has been the subject of intense study for decades. Initially, highly penetrant mutations in BRCA1 and BRCA2 were identified in families with multiple affected individuals, but together these account for less than 5% of breast cancer overall in the US (Hall et al. 1990; Pruthi et al. 2010) . The risk of a first-degree relative with breast cancer approximately doubles compared to women with no known family history of breast cancer, suggesting a more complex genetic architecture could contribute to breast cancer risk in the general population (Lichtenstein et al. 2000; Pruthi et al. 2010) .
In the last 4 years, genome-wide association studies (GWAS) have successfully discovered at least 20 distinct loci associated with risk for breast cancer (Ghoussaini and Pharoah 2009; Varghese and Easton 2010) and additional regions are expected to be discovered as meta-analyses proceed (Park et al. 2010) . Since each region identified in breast cancer GWAS appears to contribute a small fraction to the overall risk, it is not surprising that the current set explains only a small fraction of the overall familial risk for breast cancer (Ghoussaini and Pharoah 2009) . Nonetheless, the discoveries in GWAS point towards new biological insights into the underlying factors contributing to a complex disease, such as breast cancer. The follow-up for each region conclusively identified by GWAS requires fine mapping of common variants not directly tested in the GWAS to determine if one or more additional variants could be directly responsible for the signal. Since linkage disequilibrium (LD) patterns for common variants can often reveal multiple surrogates for any given marker, finemapping is necessary to nominate the subset of variants of high interest for functional investigation of the underlying biological mechanisms responsible for the direct association with breast cancer.
The Cancer Genetic Markers of Susceptibility (CGEMS) GWAS reported a single nucleotide polymorphism (SNP), rs999737, within the 14q24.1 interval that maps to an intron of the RAD51-like 1 (RAD51L1) gene. Since the most significant tagging signal rs999737 localized to an intron in RAD51L1, we conducted a fine-mapping analysis of the 14q21 region in order to better define the chromosomal boundaries of interest for subsequent biological experiments designed to explain the association signal. RAD51L1 is one of five paralogs to the gene RAD51, which encodes the eukaryotic DNA recombination repair protein (Thacker and Zdzienicka 2004; Thomas et al. 2009 ). An independent pooled analysis in the Breast Cancer Association Consortium, using data from over 40,000 cases and 40,000 controls, confirmed the association between the SNP rs999737 and breast cancer risk; the data also supported this SNP to be a risk factor for the major breast cancer subtypes, as defined by expression of estrogen-receptor, progesterone receptor, and Her2/neu (Figueroa et al. 2011) . In contrast, this SNP did not modify risk for BRCA1 or BRCA2 mutation carriers (Antoniou et al. 2011) . Molecular studies of the RAD51L1 protein suggest its main function is to promote homologous recombination repair; specifically, the protein contributes to genome integrity maintenance in response to UV-induced damages (Havre et al. 1998; Takata et al. 2000) . In breast cell lines, it has been shown that both transcription and protein levels of RAD51L1 are downregulated by over-expression of EZH2, a transcriptional repressor previously linked to aggressive and metastatic breast cancers; RAD51L1 may also partner with the protein EVL (Ena/Vasp-like) to stimulate inappropriate RAD51-mediated recombination in breast cancer cell lines (Takaku et al. 2009; Zeidler et al. 2005) .
To fine map the region surrounding rs999737 on 14q24.1, we used Stage 1 and 2 datasets from the CGEMS breast cancer GWAS to conduct an imputation analysis of SNP markers that were not directly genotyped in CGEMS. The imputation used 1000 Genomes Project (Durbin et al. 2010) and HapMap3 CEU (The International HapMap3 Consortium 2010) data. Here, we report the results of our work: the SNP marker rs999737 retains the strongest association of all imputed and genotyped SNPs across the 3.93 MB region and the data point toward a single signal on 14q24.1.
Materials and methods

Study population
As described previously (Thomas et al. 2009 ), all study subjects analyzed in the CGEMS Breast Cancer GenomeWide Association Scan were of European ancestry. Genotype data from Stage 1 and 2 of the CGEMS scan were used in this study. In Stage 1, 1,145 postmenopausal breast cancer cases and 1,142 healthy controls were genotyped with Human Hap500 Infinium Assay (Illumina) from the Nurses' Health Study (NHS) (Hunter et al. 2007 
Imputation analysis
To infer potential genomic variants tagged by the SNP rs999737, we used the hidden Markov model program, IMPUTE2 (Howie et al. 2009 ), to impute genotypes based on HapMap Phase 3 CEU data (The International HapMap3 Consortium 2010) and 1000 Genomes Project (Durbin et al. 2010) . Genotyped markers within a region of approximately 3.93 MB flanking rs999737 and RAD51L1 (chr14q21: 66, 173, 099, 944 , UCSC genome build hg18) were available for analysis, including 770 SNPs from CGEMS Stage 1 data and 41 SNPs from Stage 2 in 11,268 individuals. Based on the combined reference panels of the 1000 Genomes Projects (2010 June release) and HapMap3 CEU data (2009 February release 2), an additional 11,047 putative SNPs were imputed for Stage 1 and 2 subjects across this region of 14q24.1. The average allele dosage was estimated with 100 iterations of the imputation algorithm conditional on a set of known haplotypes while simultaneously estimating the recombination map. The best-guessed genotypes (those with highest posterior probabilities) at each SNP for each subject were also generated using GTOOL (http://www.well.ox.ac.uk/*cfreeman/software/ gwas/gtool.html). In addition to the average posterior probability for the best-guessed genotypes, the IMPUTE2-info score, which is associated with the imputed allele frequency estimate ranging from 1 (high confidence) to 0 (decreasing confidence), was also estimated for each SNP to evaluate imputation performance.
Statistical analysis
Fisher's exact tests for fitness for Hardy-Weinberg proportion (also known as Hardy-Weinberg Equilibrium, HWE) were evaluated across controls for all markers. Those that significantly deviated from HWE (P \ 10 -6 ) were discarded from further analysis. LD measures (D 0 and r 2 ) and LD plots were estimated using Haploview (Barrett et al. 2005) for the control samples. Based on the per marker quality measures generated from IMPUTE2, markers with maximum posterior genotype probability \0.9 were also filtered out to obtain reliable association results. The bestguessed SNP genotypes (those with highest posterior probabilities C0.9, imputation certainty C0.9, and did not significantly deviate from HWE) for all imputed markers were tested for association with breast cancer risk under an additive model using PLINK v1.07 (Purcell et al. 2007 ), adjusting for 10-year age groups, study sites, and 4 significant principal components to account for population heterogeneity as determined in the initial scan (Hunter et al. 2007 ; Thomas et al. 2009 ). A two-SNP model was used to determine whether an additional independent signal could be found by conditioning on the original CGEMS hit, rs999737. To explore the possible difference of the effect between different subtypes of breast cancer, we conducted a stratified analysis according to estrogen receptor (ER) and progesterone receptor (PR) status, under an additive genetic model adjusted for the already defined covariates. An analysis to account for imputation uncertainty using estimated allelic dosage was also performed with SNPTEST v2 (http://www.stats.ox.ac.uk/*marchini/software/gwas/ snptest.html) and showed similar results (data not shown). A 2-to 8-SNP sliding-window haplotype analysis was performed across the region using PLINK (Purcell et al. 2007 ). Odds ratios and P values were estimated for each haplotype versus all others, adjusted for the effects of same covariates. SequenceLDhot (Fearnhead 2006 ) was used to compute likelihood ratios (LR) for a set of putative recombination hotspots across the RAD51L1 region, repeated with 5 non-overlapping sets of 100 controls and using background recombination rates estimated by PHASE v2.1 (Stephens et al. 2001) . Snp.plotter (Luna and Nicodemus 2007) , an R-based package, was used to simultaneously display P values from single-marker and haplotype analyses.
Results
Imputation and quality control
A total of 10,273 SNP markers within a 3.93 MB flanking region (chr14:66,173,332-70,099,944) of rs999737 were imputed for 11,268 samples from the CGEMS Stages 1 and 2 of the breast cancer GWAS. Table 1 summarizes the genotyped and imputed SNPs across the 3.93 Mb region of RAD51L1. More than 60% of the imputed SNPs had a minor allele frequency greater than 1%. The overall IMPUTE2-info score was calculated to be 0.4347, the median value of all imputed markers using a measure of the performance of imputation with values ranging from 0 to 1 in ascending confidence. We did not remove SNPs with minor allele frequencies less than 5% in order to retain the less common variants that could provide evidence for a synthetic association in the region (Dickson et al. 2010 ). The association analysis was restricted to 464 SNPs, the subset of SNPs with an IMPUTE2-info score of C0.9 (a rigorous metric for high quality imputed genotype calls), and no evidence for deviation from HWE (P [ 10 -6 ). Among these SNPs, 36 were directly genotyped in both Stage 1 and 2 samples, 31 were genotyped in Stage 1 and imputed in Stage 2 and 397 were imputed based on the 1000 Genome Project and HapMap 3 data. It is notable that a subset of the SNPs genotyped in Stage 1 could not be accurately imputed in Stage 2 using the public databases.
Association analysis of surrogates for rs999737 Figure 1a shows results from single-marker analysis of all imputed and genotyped markers within chromosomal region chr14: 67795579-68450029. Among them, 46 SNPs (including, the sentinel tagging SNP, rs999737) had IMPUTE2-info scores C0.9 and did not deviate from Hardy-Weinberg equilibrium; these were also nominally associated with breast cancer risks at P adj \ 0.05, yet none of the values approached genome-wide significance ( Table 2) . 11 of the significantly associated SNPs were genotyped, while the remaining 35 were inferred from IMPUTE2 using a combined HapMap3 and 1000 Genome reference panel. Within this group, the SNP with the strongest association with breast cancer risk was the initial GWAS SNP rs999737 (P adj = 8.23 9 10 -6 ; OR adj = 0.87, 95% Cl = 0.81-0.92), as reported for Stages 1 and 2, but not Stage 3, which conducted single SNP analysis (Thomas et al. 2009 ). We performed a sequential analysis for the other 45 SNPs conditioned on rs999737 (P adjRS999737 ); 32 SNPs remained nominally associated with breast cancer risk (P adjRS999737 \0.05; Table 3 ). 5 of the SNPs were genotyped in the original GWAS report, while the remaining 28 SNPs were inferred from IMPUTE2. To determine whether the list of 45 SNPs showing moderate association with breast cancer risk were independent signals from rs999737, we examined whether any SNPs showing significant association with breast cancer risks fell across the gene RAD51L1, or shared significant pair-wise LD with the initial GWAS SNP marker, rs999737. We discovered that although 13 of the 45 SNPs generated from imputation that were statistically significant in their association with breast cancer risk were located within the coding region of RAD51L1, only 1 SNP showed nominal LD correlation with rs999737 (rs10130694; r 2 = 0.107), while others shared minimal pair-wise LD with rs999737 (Table 2) . To evaluate whether SNPs across the RAD51L1 coding region (e.g., in introns and exons) were strongly associated with breast cancer risk, we examined the group of 464 genotyped and imputed SNPs (including rs999737). We discovered that 92 SNPs were located within the RAD51L1 gene and that 12 showed minimally significant association with breast cancer risk (P adj \0.05). However, upon conditioning on rs999737, none remained significantly associated with breast cancer risk, thus suggesting that this set of markers tag a single locus.
In addition to the region proximal to rs999737 within RAD51L1, we observed several short regions with clusters of SNPs showing nominal association with breast cancer mammary gland-specific EST DA647031.The clusters of SNPs were separated from rs999737 by recombination hotspots, which we estimated based on available controls (Fig. 1a) , and the two regions shared minimal LD correlations (Table 2) .
Variable-sized sliding window haplotype analysis
Using 5 non-overlapping sets of 100 controls, randomly selected from the entire control set, we calculated and plotted the recombination pattern and LD structure for CGEMS data (Fig. 1a) . To further explore whether one or more haplotype can explain the signal, we applied a variable-sized slidingwindow haplotype analysis across the imputed region (Table 4 ; Fig. 1b ). Haplotypes inclusive of rs999737 were significantly associated with breast cancer; the strongest association was a 2-SNP haplotype between rs999737 and 14-68103993 (P value = 8.39 9 10 -6
). For rs12588940, a SNP that is 3.6 kb away from rs999737, a 7-SNP haplotype inclusive of these two SNPs remained significantly associated with breast cancer (p value = 2.13 9 10 -5 ). We examined haplotypes within the short clusters of interest, and found that they were moderately associated with breast cancer risk (chr14:68,406,986-68,410,514 interval, smallest P value = 1.36 9 10 -3 ; chr14:68,404,595-68,405,317 interval, smallest P value = 5.17 9 10 -4 ; chr14:68,399, 592-68,399,988 interval, smallest P value = 3.72 9 10 -3 ). Substantially larger independent follow-up studies will be required to determine if these signals indicate a distinct locus.
Discussion
To follow-up on the original rs999737 signal detected in the CGEMS breast cancer study (Thomas et al. 2009 ), we have conducted a fine-mapping analysis of the genomic region surrounding rs999737, which localizes to the RAD51L1 gene in the 14q21 interval (Thomas et al. 2009 ).
To explore the set of common and uncommon untested variants in this interval, we imputed SNPs based on CGEMS Stages 1 and 2 with data from the HapMap3 and 1000 Genome Project, and applied single-marker and haplotype analyses. Our study has shown that the original SNP, rs999737, retained the strongest association signal for breast cancer susceptibility in this region of 14q21, even after correcting for analysis on the discovery set.
In an analysis of SNPs from across a nearly 4 MB region on 14q24.1, we observed 46 SNPs (inclusive of rs999737) demonstrating a nominal association with breast cancer risk (P adj \ 0.05); however, the initial discovery SNP, rs999737 remained most significant in Stage 1 and 2 (P adj = 8.23 9 10 -6 ). To evaluate whether any of the signals contributed to breast cancer susceptibility independently from rs999737, we conducted a conditional analysis using the rs999737 discovery marker for the remaining 45 SNPs. While 32 SNPs retained nominal significance for breast cancer risk, in each case, the signal was attenuated. In an exploration of the correlation between each of the 45 SNPs and rs999737 in the control set, we estimated the pair-wise LD (r 2 values). None of the pairs demonstrated a high correlation and we observed residual correlation with one signal marked by rs999737 (Tables 2, 3 ). In a variable-sized sliding-window haplotype analysis (2-8 SNPs) for all genotyped and imputed SNPs, the results revealed that haplotypes containing rs999737 showed the highest association with breast cancer risk, with P value = 8.39 9 10 -6
. Thus, both single-marker and haplotype analysis suggested that the genomic element tagged by rs999737 had the strongest association with breast cancer risk (Thomas et al. 2009 ).
To determine whether the imputed SNPs exhibited different effects for distinct breast cancer subtypes, specifically, ER and PR subtypes, we conducted a stratified analysis in those cases with reliable ER/PR status (approximately 80%). Supplementary Table 1 shows results for the top 46 SNPs (inclusive of rs999737) with Pair-wise linkage disequilibrium (r 2 with rs999737) with rs999737 was calculated and no significant LD was shared between rs999737 and any of these SNPs. OR (95%CI) and p-values were estimated from logistic regression with an additive genetic effect, adjusted for age (in 10-year categories), study sites, and 4 significant principle components a Genomic coordinates are based on NCBI Human Genome Build 36.3 b SNP marker sources. GWAS-P1: actual genotyped SNPs in CGEMS GWAS Phase 1; GWAS-P2: actual genotyped SNPs in CGEMS GWAS Phase 2; 1kG: imputed SNPs based on 1000 Genomes Project data; HM3: imputed SNPs based on HapMap Phase 3 data c A1 marks the minor allele; A2 marks the major allele d Minor allele frequency (MAF) for cases (CS) and controls (CN) e Estimates from logistic regression with an additive genetic effect, adjusted for age (in 10-year categories), study sites, and 4 significant principle components Hum Genet (2012) 131:479-490 485 Table 3 Thirty-two imputed and genotyped SNPs with nominally significant association after sequential conditioning on rs999737 ( nominal association with breast cancer (Table 2) in this study, stratified by each of ER and PR status. Our data suggest that compared with ER-negative tumors, a subset of SNPs had evidence for a stronger association with ERpositive breast cancer than in ER-negative tumors. This might be due to the predominance of ER-positive subjects among breast cancer cases. The analysis stratified by PR status was unremarkable. As genome-wide association studies can detect disease susceptibility loci throughout multi-stage study design, there might be potential bias introduced by ''winner's curse'' effect (Capen et al. 1971) in the SNP selection process of replication studies (Zhong and Prentice 2008) . In our analysis, we conducted the fine-mapping in the same set used to discover the tag SNP, rs999737. We recognized that there could be a bias away from the null in favor of the discovered tag SNP (Zhong and Prentice 2008) . Here, we calculated the bias-reduced estimators and confidence intervals using a recently proposed method Prentice 2008, 2009 ) for top SNPs reported in the present study. The bias-adjusted OR and 95% CI were slightly weaker than the unadjusted estimates but maintained good concordance with unadjusted estimates (Supplementary  Table 2 ). In our study of approximately 5,600 cases and 5,600 controls, we had sufficient power to detect variants with minor allele frequency [0.15 and odds ratio greater than 1.20 assuming a disease prevalence of 12% at the significance level of P \ 5 9 10 -6 (Supplementary  Table 3) .
Our results did not identify new strong signals across the large region extending well beyond the recombination hot spots confirmed in our analysis. In this regard, we did not identify a second locus or a substantially better tag SNP than the originally reported SNP, rs999737, suggesting that the common variant signal associated with breast cancer is most likely due to a single locus on chromosome 14q24.1. Functional analysis of the tag SNP and its highly correlated variants will be needed to define the underlying mechanism and to establish the variant(s) that confer the direct association.
In an exploration of a nearly 4 MB interval, we examined the genomic landscape for each of the 32 SNPs noted above in search of possible biological mechanisms that might be worth pursuit, by either laboratory investigation or by extending the replication effort (Table 3) . Several clusters of variants map to regions previously related to breast cancer ( Fig. 1b ; mammary gland specific EST AK022224: chr14:68,406,968-68,410,613; rs71824488: chr14:68,402,332-68,405,672 ; mammary gland specific EST DA647031: chr14:68,399,325-68,400,050). A cluster of 6 SNPs is within the mammary gland-specific EST, AK02224; a second cluster of 6 SNPs localizes within a polymorphic indel of 2.841 bp on the ? strand, marked by the SNP rs71824488; the third cluster of 3 SNPs localizes to another mammary gland-specific EST, DA647031. We also observed possible signals separate from the signal marked by rs999737, but additional studies will be needed to determine if any of these represent independent loci. It is likely that the additional signals either reflect residual LD across this region, still pointing to the single locus marked by rs999737, or that these observations are due to chance.
RAD51L1 is a paralog of the RAD51 gene, and it forms a complex with RAD51L2 in the homologous recombination repair pathway through the complex's ability to catalyze DNA strand-exchange (Hussain et al. 2004; Miller et al. 2002; Sigurdsson et al. 2001) . Interestingly, akin to RAD51L1, RAD51L2 was also identified as a breast cancer susceptibility gene (Meindl et al. 2010) . In addition to the RAD51 paralogs, other homologous recombination repair pathways genes have also been associated with breast cancer susceptibility, such as ATM, CHEK2, BRCA1 and BRCA2 (Hollestelle et al. 2010) . It is also noteworthy that RAD51L1 had previously been identified as a fusion gene in myeloid malignancies, thymoma and autoimmune diseases (Nicodeme et al. 2005; Odero et al. 2005) . Together, these observations suggest that genetic variation, both germ-line and somatic, within this region could contribute to one or more oncogenic processes. 
